What Researchers Did
Israeli researchers reviewed the molecular mechanisms underlying HBOT and the evidence for its effectiveness in treating a range of neurological conditions, including hypoxia-related disorders, autism spectrum disorder, and cerebral palsy.
What They Found
HBOT increases oxygen delivery to hypoxic tissues, stimulates angiogenesis, reduces neuroinflammation, and supports mitochondrial function. Evidence in animals and some human studies supports its use across neurological conditions, though evidence quality varies considerably by condition. The review identifies significant gaps in understanding optimal pressure, duration, and patient selection criteria.
What This Means for Canadian Patients
For Canadian families of children with cerebral palsy or autism, and for adults with acquired neurological conditions, this review outlines the biological rationale for HBOT, though it also honestly notes that robust clinical evidence for many indications remains limited.
Canadian Relevance
No direct Canadian connection identified. Several of the neurological conditions discussed affect large numbers of Canadians, making advances in evidence-based HBOT protocols highly relevant.
Study Limitations
As a narrative review, it does not apply systematic methods to weigh evidence quality, and optimistic pre-clinical findings are not always reproducible in human trials.